4005-46-3

Basic information

• Product Name: (1R)-1-[(3aR,5R,6aR)-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxol-5-yl]ethane-1,2-diol
• Synonyms: (1R)-1-[(3aR,5R,6aR)-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxol-5-yl]ethane-1,2-diol
• CAS NO: 4005-46-3
• Molecular Weight: 204.223
• Mol File: 4005-46-3.mol
• Article Data: 37

Chemical Properties

• CAS DataBase Reference: (1R)-1-[(3aR,5R,6aR)-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxol-5-yl]ethane-1,2-diol(CAS DataBase Reference)
• NIST Chemistry Reference: (1R)-1-[(3aR,5R,6aR)-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxol-5-yl]ethane-1,2-diol(4005-46-3)
• EPA Substance Registry System: (1R)-1-[(3aR,5R,6aR)-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxol-5-yl]ethane-1,2-diol(4005-46-3)

Safety Data

• Hazardous Substances Data: 4005-46-3(Hazardous Substances Data)

Upstream product

• 4613-62-1 3-deoxy-1,2;5,6-di-O-isopropylidene-α-D-glucofuranoside 
• 96852-88-9 3,5,6-trideoxy-1,2-O-isopropylidene-α-D-ribo-hex-5-enofuranoside 
• 6027-62-9 3-deoxy-3-iodo-1,2:5,6-di-O-isopropylidene-α-D-allofuranose 
• 114192-72-2 3-deoxy-3-iodo-1,2-O-isopropylidene-α-D-allofuranose 
• 582-52-5 1,2:5,6-di-O-isopropylidene-α-D-glucofuranose 
• 32785-98-1 3-deoxy-1,2:5,6-di-O-isopropylidene-β-D-lyxo-hexose 
• 38166-60-8 1,2:5,6-di-O-isopropylidene-α-L-glucofuranoside 
• 100638-80-0 1,2:5,6-di-O-isopropylidene-3-O-(methylthio)thiocarbonyl-β-D-idose 
• 79233-85-5 O-[1,2:5,6-di-O-isopropylidene-α-D-glucofuranosyl] 1H-imidazole-1-carbothioate 
• 2774-29-0 (3aR,5R,6aR)-5-[(4R)-2,2-dimethyl-1,3-dioxolan-4-yl]-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxole 
• 10368-86-2 1,2:5,6-di-O-isopropylidene-α-D-galactofuranose 
• 55951-93-4 1,2:5,6-di-O-isopropylidene-3-O-triflyl-α-D-glucofuranose 
• 582-52-5 1,2:5,6-diacetone-D-glucose 
• 16667-96-2 O-[(3aR,5R,6S,6aR)-5-(2,2-dimethyl-1,3-dioxolan-4-yl)-2,2-dimethyl-3a,5,6,6a-tetrahydrofuro[2,3-d][1,3]dioxol-6-yl] methylsulfanylmethanethioate 

Downstream Products

• 158226-39-2 3-deoxy-1,2-O-isopropylidene-6-O-(2,4,6-trimethylbenzenesulfonyl)-α-D-ribo-hexofuranose 
• 158226-41-6 6-O-tert-butyldiphenylsilyl-3-deoxy-1,2-O-isopropylidene-α-D-ribo-hexofuranose 
• 22323-55-3 3-deoxy-1,2-O-isopropylidene-6-O-tosyl-α-D-xylo-hexofuranose 
• 75646-88-7 3-deoxy-1,2-O-isopropylidene-5,6-di-O-tosyl-α-D-xylo-hexofuranose 
• 896110-06-8 (3aR,5S,6aR)-2,2-Dimethyl-5-((1S,2S)-2-phenylsulfanylmethyl-cyclopropyl)-tetrahydro-furo[2,3-d][1,3]dioxole 
• 855855-55-9 (3aR,5S,6aR)-2,2-Dimethyl-5-((E)-styryl)-tetrahydro-furo[2,3-d][1,3]dioxole 
• 855855-56-0 (2R,4R)-6-Phenyl-hexane-1,2,4-triol 
• 855855-64-0 (2S,3R,5R)-5-Phenethyl-tetrahydro-furan-2,3-diol 
• 855855-54-8 (3aR,5R,6aR)-2,2-Dimethyl-5-phenethyl-tetrahydro-furo[2,3-d][1,3]dioxole 
• 855855-52-6 Benzoic acid (S)-1-(R)-1-oxiranylmethyl-3-phenyl-propyl ester 
• 855855-57-1 (R)-1-((R)-2,2-Diethyl-[1,3]dioxolan-4-yl)-4-phenyl-butan-2-ol 
• 855855-58-2 Benzoic acid (1S,3R)-3,4-dihydroxy-1-phenethyl-butyl ester 
• 855855-65-1 Benzoic acid (S)-1-((R)-2,2-diethyl-[1,3]dioxolan-4-ylmethyl)-3-phenyl-propyl ester 
• 855855-66-2 Benzoic acid (1S,3R)-3-hydroxy-1-phenethyl-4-(toluene-4-sulfonyloxy)-butyl ester 

Relevant articles and documents

Total synthesis of a novel isoprostane IPF(2α)-I and its identification in biological fluids

The first tokai synthesis of IPF(2α)-I 25 is described using D-glucose as starting material. This novel isoprostane has been used to establish its presence in human urine.

Novel oxolane derivative DMTD mitigates high glucose-induced erythrocyte apoptosis by regulating oxidative stress

Chronic hyperglycemia is one of the characteristic conditions associated with Diabetes Mellitus (DM), which often exerts deleterious effects on erythrocyte morphology and hemodynamic properties leading to anemia and diabetes-associated vascular complications. High glucose-induced over production of reactive oxygen species (ROS) can alter the blood cell metabolism and biochemical functions subsequently causing eryptosis (red blood cell death), yet another complication of concern in DM. Therefore, blocking high glucose-induced oxidative damage and subsequent eryptosis is of high importance in the better management of DM and associated vascular complications. In this study, we synthesized an oxolane derivative 1-(2,2-dimethyltetrahydrofuro[2,3][1,3]dioxol-5-yl)ethane-1,2-diol (DMTD), and demonstrated its efficacy to mitigate hyperglycemia-induced ROS generation and subsequent eryptosis. We showed that DMTD effectively inhibits high glucose-induced ROS generation, intracellular calcium levels, phosphaditylserine (PS) scrambling, calpain and band 3 activation, LDH leakage, protein glycation and lipid peroxidation, meanwhile enhances the antioxidant indices, osmotic fragility and Na+/K+-ATPase activity in erythrocytes. DMTD dose dependently decreased the glycated hemoglobin level and enhances the glucose utilization by erythrocytes in vitro. Further, DMTD alleviated the increase in ROS production, intracellular Ca2 + level and PS externalization in the erythrocytes of human diabetic subjects and enhanced the Na+/K+-ATPase activity. Taken together, the synthesized oxolane derivative DMTD could be a novel synthetic inhibitor of high glucose-induced oxidative stress and eryptosis. Considering the present results DMTD could be a potential therapeutic to treat DM and associated complications and open new avenues in developing synthetic therapeutic targeting of DM-associated complications.

TLR7 AGONISTS

The present invention relates to TLR7 agonists according to Formula I and their use in the treatment of diseases such as cancer and infectious disease.

PROCESS FOR THE PREPARATION OF 3-SUBSTITUTED 5-AMINO-6H-THIAZOLO[4,5-d]PYRIMIDINE-2,7-DIONE COMPOUNDS

The present invention relates to a process for synthesizing a compound of formula (I), R1 is H or C1-6alkyl; R2 is H or hydroxy; or pharmaceutically acceptable salt or diastereomer thereof, which is useful for prophylaxis